It is a composite test that includes an immunochemical analysis, methylated biomarkers (ex: BMP3 and NDRG4), and genetic mutations (e.g., KRAS and ACTB) associated with CRC [80,81,84]. This evidence concerns the gene ACTB and colorectal carcinoma.